Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1875 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Enterprise Therapeutics–SEVERAL: investment, 202401 financing round Series B follow-on £26m led by Panakès Partners 2024-01-30
BioLizard–MC Services: public relations, 202401 service existent by MC Services 2024-01-23
Disco Pharmaceuticals–SEVERAL: investment, 202401 seed financing round €20m led by Sofinnova Partners 2024-01-16
Aiolos Bio–GSK: investment, 202401– acquisition $1b upfront + $400m milestones 2024-01-09
Calypso Biotech–Novartis: investment, 202401– acquisition $250m upfront + $175m milestones by Novartis SIGNED 2024-01-08
Full-Life Technologies–OTHER: credit, 202401– loan facility $16m 2024-01-04
Full-Life Technologies–SEVERAL: investment, 202401 financing round Series B $47.3m led by Prosperity7 Ventures + undisclosed healthcare investor 2024-01-04
Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter 2023-12-23
Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ 2023-12-21
Shinobi Therapeutics–EQT: investment, 202312 financing round Series A totalling $51m incl co-lead investor EQT Life Sciences 2023-12-12
Shinobi Therapeutics–SEVERAL: investment, 202312 financing round Series A $51m led by EQT LS + F-Prime Capital + Eight Roads Ventures Japan 2023-12-12
IBA (BE)–Univ Kansas: proton therapy, 202312– colllab research using ConformalFLASH technology on ProteusONE system with KUMC 2023-12-05
Bioxodes–SEVERAL: investment, 202311 financing round Series A €8.6m from existing investors 2023-11-21
Bioxodes–Wallonia (govt): grant, 202311 non-dilutive funding €3.4m from Walloon region 2023-11-21
RED Horticulture–Demeter: investment, 202311 financing round Series A totalling €17m incl existing investor Demeter IM 2023-11-21
RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF 2023-11-21
RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains 2023-11-21
RED Horticulture–Unigrains: investment, 202311 financing round Series A totalling €17m incl new investor Unigrains 2023-11-21
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital 2023-11-15
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures 2023-11-14
VectorY–ALS Investment Fund: investment, 202311 financing round Series A totalling €129m incl co-investor ALS Investment Fund 2023-11-13
VectorY–BioGeneration Ventures: investment, 202311 financing round Series A totalling €129m incl existing + co-investor BGV 2023-11-13
VectorY–EQT: investment, 202311 financing round Series A totalling €129m incl new + co-lead investor EQT Life Sciences Dementia Fund 2023-11-13
VectorY–Forbion: investment, 202311 financing round Series A totalling €129m incl existing + co-lead investor Forbion GOF + Forbion Ventures 2023-11-13
VectorY–Insight Partners: investment, 202311 financing round Series A totalling €129m incl co-investor Insight Partners 2023-11-13
VectorY–Merck (US): investment, 202311 financing round Series A totalling €129m incl co-investor MRL Ventures Fund 2023-11-13
VectorY–OTHER: investment, 202311 financing round Series A totalling €129m incl another known investor 2023-11-13
VectorY–SEVERAL: investment, 202311 financing round Series A €129m co-led by EQT Life Sciences + Forbion Growth Opportunities Fund 2023-11-13
ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures 2023-11-13
ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures 2023-11-13
Kynexis–Forbion: investment, 202311 financing round Series A totalling €57m incl co-founding + lead investor Forbion 2023-11-07
Kynexis–SEVERAL: investment, 202311 financing round Series A €57m led by Forbion 2023-11-07
Kynexis–Sunstone Life Science: investment, 202311 financing round Series A totalling €57m incl co-investor Sunstone Life Science Ventures 2023-11-07
Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital 2023-11-07
Kynexis–Mitsubish Chemical: KAT-II inhibitor, 202311c– license excl ww rights to develop + commercialize KYN-5356 from MTPC 2023-11-01
Aiolos Bio–Forbion: investment, 202310 financing round Series A totalling $245m incl co-lead investor Forbion 2023-10-25
Aiolos Bio–SEVERAL: investment, 202310 financing round Series A $245m co-led by Atlas Venture + Bain + Forbion + Sofinnova Investments with RA Capital 2023-10-24
Agomab Therapeutics–Canaan Partners: investment, 202310 financing round Series C totalling $100m incl new + co-investor Canaan 2023-10-10
Agomab Therapeutics–EQT: investment, 202310 financing round Series C totalling $100m incl new + co-investor EQT Life Sciences 2023-10-10
Agomab Therapeutics–Fidelity: investment, 202310 financing round Series C totalling $100m incl lead investor Fidelity Mgt and Research 2023-10-10
Agomab Therapeutics–KKR: investment, 202310 financing round Series C totalling $100m incl new + co-investor Dawn Biopharma 2023-10-10
Agomab Therapeutics–OTHER: investment, 202310 financing round Series C totalling $100m incl existing investors 2023-10-10
Agomab Therapeutics–SEVERAL: investment, 202310 financing round Series C $100m (€94.9m) led by Fidelity Mgt and Research Company 2023-10-10
AstronauTx–SEVERAL: investment, 202310 financing round Series A £48m led by Novartis Venture Fund 2023-10-09
Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand 2023-09-28
Kern Tec–EU (govt): investment, 202309 financing round Series A totalling €12m incl co-investor EIC Fund 2023-09-27
Kern Tec–PeakBridge: investment, 202309 financing round Series A totalling €12m incl co-investor PeakBridge Growth 2 fund 2023-09-27
Kern Tec–SEVERAL: investment, 202309 financing round Series A €12m led by Telos Impact (eventually total includes grants?) 2023-09-27
Kern Tec–Telos Impact: investment, 202309 financing round Series A totalling €12m incl lead investor Telos Impact 2023-09-27
Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services 2023-09-20
Aboleris Pharma–SEVERAL: investment, 202309 financing round Series A €23.7m led by Caixa Capital Risc + co-led by Sound Bioventures 2023-09-18
Broken String Biosciences–Heran Partners: investment, 202309 financing round Series A totalling $15m incl new + co-investor Heran Partners 2023-09-18
Moderna–Immatics: cancer drugs, 202309– strategic r+d collab $120m upfront + >$1.7b funding + milestones + royalties combing tech platforms 2023-09-11
Paptic–SEVERAL: investment, 202309 financing round Series A €23m led by ECBF + incl Ecolab + Itochu Fibre 2023-09-04
Inversago Pharma–Novo Group: investment, 202308– acquisition up to $1.075b in cash by Novo Nordisk A/S 2023-08-10
Aiolos Bio–Hengrui: TSLP-antibody, 202308– acquisition ww excl developm + commercialisation rights to AIO-001 outside of Greater China 2023-08-01
Inversago Pharma–Forbion: investment, 202308 existent shareholder Forbion 2023-08-01
Argenx–SEVERAL: investment, 202307 global offering €979.6m via ADS offering in US + private placement in Europe 2023-07-17
BioGeneration Ventures–BMS: investment, 202307 closing of BGV V totalling €150m incl existing investor BMS 2023-07-13
BioGeneration Ventures–Lilly: investment, 202307 closing of BGV V totalling €150m incl existing investor Eli Lilly 2023-07-13
BioGeneration Ventures–Novo Group: investment, 202307 closing of BGV V totalling €150m incl existing investor Novo Holdings 2023-07-13
BioGeneration Ventures–SEVERAL: investment, 202307 closing of BGV V with €150m incl Lilly + Novo Holdings + BMS et al 2023-07-13
Aphea.Bio–SEVERAL: investment, 202307 financing round Series C €70m led by Innovation Industries 2023-07-11
TolerogenixX–Bruchmann Group: investment, 202307 financing round Series A 2nd closing totalling €7m incl new investor DB Speciality 2023-07-06
TolerogenixX–SEVERAL: investment, 202307 financing round Series A 2nd closing €7m bringing total round to €11.6m 2023-07-06
Rewind Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam 2023-07-05
River BioMedics–SEVERAL: investment, 202307 seed financing round €2m bringing total seed funding to €3.8m 2023-07-05
Versanis Bio–Forbion: investment, 202307 existent shareholder Forbion 2023-07-01
Versanis Bio–Lilly: investment, 202307– acquisition up to $1.925b 2023-07-01
Astraveus–Merck (DE): investment, 202306 seed financing round totalling €16.5m incl co-investor M Ventures 2023-06-27
Astraveus–SEVERAL: investment, 202306 seed financing round €16.5m led by AdBio Partners 2023-06-27
Carthera–EU (govt): investment, 202306 financing round Series B totalling €37.5m incl co-investor EIC Fund 2023-06-27
Carthera–Panakès Partners: investment, 202306 financing round Series B totalling €37.5m incl existing + co-investor Panakès Partners 2023-06-27
Carthera–SEVERAL: investment, 202306 financing round Series B €37.5m led by undisclosed investor 2023-06-27
NLC Ventures–SEVERAL: investment, 202306 1st closing €20m of NCL Health Impact Fund from private investors targeting €100m 2023-06-26
Tagworks Pharmaceuticals–Argot Partners: public relations, 202306 service existent media + investor contact Argot Partners 2023-06-22
Tagworks Pharmaceuticals–Gilde Investment: investment, 202306 financing round Series A totalling $65m incl co-lead investor Gilde Healthcare 2023-06-22
Tagworks Pharmaceuticals–Lightstone Ventures: investment, 202306 financing round Series A totalling $65m incl co-investor Lightstone Ventures 2023-06-22
Tagworks Pharmaceuticals–New Enterprise Associates: investment, 202306 financing round Series A totalling $65m incl co-investor NEA 2023-06-22
Tagworks Pharmaceuticals–Novartis: investment, 202306 financing round Series A totalling $65m incl co-investor Novartis Venture Fund 2023-06-22
Tagworks Pharmaceuticals–SEVERAL: investment, 202306 financing round Series A $65m led by Ysios Capital + Gilde Healthcare 2023-06-22
Tagworks Pharmaceuticals–Ysios Capital: investment, 202306 financing round Series A totalling $65m incl co-lead investor Ysios Capital 2023-06-22
Innovative Health Initiative–EU (govt): grant, 202306– funding €24m for IMAGIO project from IHI 2023-06-20
Innovative Health Initiative–Philips: targeted cancer therapy, 202306– Philips is coordinating partner ot the IMAGIO project of IHI 2023-06-20
Innovative Health Initiative–Thermosome: targeted cancer therapy, 202306– Thermosome is partner in IMAGIO project of IHI 2023-06-20
Thermosome–Innovative Health Initiative: grant, 202306– funding €1.3m as partner in IMAGIO project of IHI 2023-06-20
Danish National Genome Center–Qiagen: genomic software tools, 202306– supply QCI Interpret software for oncology genome sequencing by Qiagen 2023-06-13
Santero Therapeutics–Belgium (govt): investment, 202306 financing round Series A totalling €8m incl co-investor SFPIM 2023-06-07
Santero Therapeutics–Newton Biocapital: investment, 202306 financing round Series A totalling €8m incl lead investor Newton Biocapital 2023-06-07
Santero Therapeutics–OTHER: investment, 202306 financing round Series A totalling €8m incl a group of business angels led by Pierre Drion 2023-06-07
Santero Therapeutics–Sambrinvest: investment, 202306 financing round Series A totalling €8m incl co-investor Sambrinvest 2023-06-07
Santero Therapeutics–SEVERAL: investment, 202306 financing round Series A €8m led by Newton Biocapital 2023-06-07
Santero Therapeutics–Wallonia (govt): investment, 202306 financing round Series A totalling €8m incl co-investor WE Life Sciences 2023-06-07
AAVantgarde Bio–SEVERAL: investment, 202306 financing round Series A €61m led by Atlas Venture + Forbion 2023-06-06
Synaffix–Lonza: investment, 202306 acquisition €100m upfront cash + €60m milestones of Synaffix by Lonza 2023-06-01
Mithra Pharmaceuticals–BioConfidant: public relations, 202305 service existent by Cohesion Bureau 2023-05-29
Michor Consulting–QbD Group: investment, 202305 acquisition of Michor Consulting by QbD Group 2023-05-25
Turnstone Communications–QbD Group: investment, 202305 acquisition of Turnstone Communications by QbD Group 2023-05-25
VarmX–ABP (NL): investment, 202305 financing round Series B2 totalling €30m incl existing + co-investor Inkef 2023-05-25
VarmX–BioGeneration Ventures: investment, 202305 financing round Series B2 totalling €30m incl existing + co-investor BGV 2023-05-25
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  next pagenext page



Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top